Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02541942 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02541942 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 19 participants.
The verdict
NCT02541942, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547). The objective is to determine the HLA (human leukocyte antigen) type and polymorphisms in the FVII gene in patients previously exposed to rFVIIa analogue.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-04-03 |
| Est. Completion | 2016-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02541942
The ClinicalTrials.gov registry entry for NCT02541942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT02541942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02541942 about?
NCT02541942 is a clinical study titled "Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial". This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547). The objective is to determine the HLA (human leukocyte antigen) type and polymorphisms in the FVII gene in patients previo...
What is the current status of trial NCT02541942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2015-04-03. Estimated completion is 2016-04-15.
What interventions are being tested in trial NCT02541942?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT02541942?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.